GEN1 promotes common fragile site expression.
CP: Molecular biology
DNA damage
MiDAS
anaphase bridge
recombination
replication
replication stress
resolution
Journal
Cell reports
ISSN: 2211-1247
Titre abrégé: Cell Rep
Pays: United States
ID NLM: 101573691
Informations de publication
Date de publication:
28 02 2023
28 02 2023
Historique:
received:
23
02
2022
revised:
01
11
2022
accepted:
18
01
2023
medline:
4
10
2023
pubmed:
3
2
2023
entrez:
2
2
2023
Statut:
ppublish
Résumé
Our genomes harbor conserved DNA sequences, known as common fragile sites (CFSs), that are difficult to replicate and correspond to regions of genome instability. Following replication stress, CFS loci give rise to breaks or gaps (termed CFS expression) where under-replicated DNA subsequently undergoes mitotic DNA synthesis (MiDAS). We show that loss of the structure-selective endonuclease GEN1 reduces CFS expression, leading to defects in MiDAS, ultrafine anaphase bridge formation, and DNA damage in the ensuing cell cycle due to aberrant chromosome segregation. GEN1 knockout cells also exhibit an elevated frequency of bichromatid constrictions consistent with the presence of unresolved regions of under-replicated DNA. Previously, the role of GEN1 was thought to be restricted to the nucleolytic resolution of recombination intermediates. However, its ability to cleave under-replicated DNA at CFS loci indicates that GEN1 plays a dual role resolving both DNA replication and recombination intermediates before chromosome segregation.
Identifiants
pubmed: 36729836
pii: S2211-1247(23)00073-6
doi: 10.1016/j.celrep.2023.112062
pii:
doi:
Substances chimiques
DNA
9007-49-2
DNA-Binding Proteins
0
Endonucleases
EC 3.1.-
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
112062Subventions
Organisme : Cancer Research UK
ID : CC2098
Pays : United Kingdom
Organisme : Medical Research Council
ID : CC2098
Pays : United Kingdom
Organisme : Wellcome Trust
ID : CC2098
Pays : United Kingdom
Informations de copyright
Copyright © 2023 The Author(s). Published by Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of interests The authors declare no conflict of interest.